Ahmed O. Kaseb

机构：The University of Texas MD Anderson Cancer Center, Scripps MD Anderson Cancer Center · ORCID：0000-0002-9491-0587

发表论文 541 篇 · 总被引 26952 次 · h-index 66

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 25)
• Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinoma (2025 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 7)
• Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study (2025 · JHEP Reports · 被引 2)
• 478 Spatial omics and deep learning define an immunotherapy resistance niche in hepatocellular carcinoma (2025 · Regular and Young Investigator Award Abstracts · 被引 2)
• Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma (2025 · Journal of Gastrointestinal Cancer · 被引 2)
• Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits (2025 · International Journal of Cancer · 被引 2)